MA52941A - Dérivés de thiophène pour le traitement de troubles provoqués par ige - Google Patents

Dérivés de thiophène pour le traitement de troubles provoqués par ige

Info

Publication number
MA52941A
MA52941A MA052941A MA52941A MA52941A MA 52941 A MA52941 A MA 52941A MA 052941 A MA052941 A MA 052941A MA 52941 A MA52941 A MA 52941A MA 52941 A MA52941 A MA 52941A
Authority
MA
Morocco
Prior art keywords
ige
treatment
thiophene derivatives
caused disorders
disorders
Prior art date
Application number
MA052941A
Other languages
English (en)
Inventor
Prafulkumar Tulshibhai Chovatia
Rickki Lee Connelly
Richard Jeremy Franklin
Gregory William Haslett
Alistair James Henry
James Madden
Judi Charlotte Neuss
Timothy John Norman
Oliver Philps
William Ross Pitt
Konstantinos Rampalakos
Matthew Duncan Selby
Suganthan Selvaratnam
Giancarlo Trani
Zhaoning Zhu
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MA52941A publication Critical patent/MA52941A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA052941A 2018-06-21 2019-06-20 Dérivés de thiophène pour le traitement de troubles provoqués par ige MA52941A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18179126 2018-06-21

Publications (1)

Publication Number Publication Date
MA52941A true MA52941A (fr) 2021-04-28

Family

ID=62748855

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052941A MA52941A (fr) 2018-06-21 2019-06-20 Dérivés de thiophène pour le traitement de troubles provoqués par ige

Country Status (22)

Country Link
US (1) US12018021B2 (fr)
EP (1) EP3810606A1 (fr)
JP (1) JP7657056B2 (fr)
KR (1) KR102850569B1 (fr)
CN (1) CN112566910B (fr)
AR (1) AR114973A1 (fr)
AU (1) AU2019291111B9 (fr)
BR (1) BR112020025510A2 (fr)
CA (1) CA3103052A1 (fr)
CL (1) CL2020003191A1 (fr)
EA (1) EA202190011A1 (fr)
EC (1) ECSP20080272A (fr)
IL (1) IL279482B2 (fr)
MA (1) MA52941A (fr)
MX (1) MX2020013882A (fr)
PE (1) PE20211803A1 (fr)
PH (1) PH12020552162A1 (fr)
PY (1) PY1949665A (fr)
SG (1) SG11202012308TA (fr)
TW (1) TW202016107A (fr)
UY (1) UY38271A (fr)
WO (1) WO2019243550A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220193080A1 (en) * 2019-04-11 2022-06-23 University Of The Sciences Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor
CN113811324B (zh) * 2019-05-10 2024-09-24 达纳-法伯癌症研究公司 小分子局部黏着斑激酶(fak)抑制剂
GB201919213D0 (en) 2019-12-23 2020-02-05 Ucb Biopharma Sprl Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds
GB201919214D0 (en) * 2019-12-23 2020-02-05 Ucb Biopharma Sprl Tetrahydrobenzo-quinoline sulfonamide derivatives useful as IGE modulators
CN116531369A (zh) * 2023-02-24 2023-08-04 杜娟娟 一种化合物在促进伤口愈合药物中的应用
KR20260006567A (ko) * 2023-03-21 2026-01-13 뉴러식 테라퓨틱스 인코포레이티드 치환된 티오펜 융합 시클로헥사논 유도체, 이를 포함하는 조성물, 및 의약품으로서의 이들의 용도
KR20260032992A (ko) * 2023-06-05 2026-03-10 셀로람 인코포레이티드 지방산 결합 단백질(fabps) 억제제, 그 사용 방법, 및 제조 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU616916B2 (en) * 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
WO2001017516A2 (fr) * 1999-09-10 2001-03-15 Novo Nordisk A/S Procede d'inhibition de la proteine tyrosine phosphatase 1b et/ou de la proteine tyrosine phosphatase de lymphocytes et/ou d'autres ptpases possedant un reste aps en position 48
JP4548882B2 (ja) 1999-11-30 2010-09-22 興和創薬株式会社 ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン化合物
JP2001151789A (ja) * 1999-11-30 2001-06-05 Kao Corp アルキルグリコシドの製造方法
US20030199571A1 (en) * 1999-12-24 2003-10-23 Gordon Bruton (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040171603A1 (en) 2001-05-18 2004-09-02 Janos Pato Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor
US20070275962A1 (en) * 2003-09-10 2007-11-29 Gpc Biotech Ag Heterobicyclic Compounds as Pharmaceutically Active Agents
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
GB0324653D0 (en) * 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
EP1891028A1 (fr) 2005-05-18 2008-02-27 Forschungsverbund Berlin e.V. Inhibiteurs non peptidiques de l'interaction akap-pka
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20110015239A1 (en) * 2007-12-14 2011-01-20 The Regents Of The University Of California Inhibitors of calcium-activated chloride channels
PE20160286A1 (es) * 2013-08-08 2016-05-22 Galapagos Nv DERIVADOS DE TIENO [2,3-c] PIRANO Y SUS COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE LA FIBROSIS QUISTICA

Also Published As

Publication number Publication date
PY1949665A (es) 2019-12-26
AU2019291111B9 (en) 2023-08-24
AU2019291111B2 (en) 2023-07-06
PE20211803A1 (es) 2021-09-14
AR114973A1 (es) 2020-11-11
CN112566910A (zh) 2021-03-26
CN112566910B (zh) 2025-09-09
PH12020552162A1 (en) 2021-06-28
CL2020003191A1 (es) 2021-07-02
EA202190011A1 (ru) 2021-04-27
JP2021527665A (ja) 2021-10-14
AU2019291111A1 (en) 2021-01-21
US20220332709A1 (en) 2022-10-20
KR102850569B1 (ko) 2025-08-26
US12018021B2 (en) 2024-06-25
IL279482B2 (en) 2024-11-01
WO2019243550A1 (fr) 2019-12-26
BR112020025510A2 (pt) 2021-03-09
MX2020013882A (es) 2021-05-27
ECSP20080272A (es) 2021-01-29
TW202016107A (zh) 2020-05-01
IL279482A (en) 2021-01-31
SG11202012308TA (en) 2021-01-28
EP3810606A1 (fr) 2021-04-28
JP7657056B2 (ja) 2025-04-04
IL279482B1 (en) 2024-07-01
KR20210024571A (ko) 2021-03-05
CA3103052A1 (fr) 2019-12-26
UY38271A (es) 2020-01-31

Similar Documents

Publication Publication Date Title
MA52941A (fr) Dérivés de thiophène pour le traitement de troubles provoqués par ige
EP3634417A4 (fr) Dérivés quinazoline-pyrazole pour le traitement de troubles liés au cancer
MA51046A (fr) Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP2970099A4 (fr) Dérivés de 3-phénylpropylamine substitués pour le traitement des maladies et des troubles ophtalmiques
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3938340A4 (fr) Dérivés aromatiques hétérobicycliques et hétéroaromatiques pour le traitement de troubles liés à la ferroptose
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
EP3774743C0 (fr) Composés de type promédicaments activés par akr1c3 et leur utilisation pour le traitement de troubles hyperprolifératifs
EP3445451A4 (fr) Compositions et méthodes pour le traitement de troubles lysosomaux et de troubles caractérisés par un dysfonctionnement lysosomal
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
EP3454896A4 (fr) Dérivés hétérocycliques pour le traitement de rsv
EP3941462A4 (fr) Composés pharmaceutiques pour le traitement de troubles médiés par le complément
EP3898991A4 (fr) Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3723768A4 (fr) Composés pour le traitement et la prévention de pathologies médiées par l'histone extracellulaire
EP3621434A4 (fr) Méthodes de traitement de troubles neuropsychiatriques
EP3612214A4 (fr) Optimisation d'enzymothérapie de remplacement pour le traitement de l'homocystinurie
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
MA51738A (fr) Composés pour le traitement de la douleur